Investigação de mutações no gene PCSK9 em famílias com diagnóstico clínico de Hipercolesterolemia Familiar

Investigação de mutações no gene PCSK9 em famílias com diagnóstico clínico de Hipercolesterolemia Familiar

A hipercolesterolemia familiar (HF) é uma alteração de origem genética comum que pode se manifestar clinicamente desde o nascimento e provoca um aumento nos níveis plasmáticos de LDL-colesterol (LDL-c), xantomas e doença coronária prematura. Sua detecção e tratamento precoce reduzem a morbidade e mo...

Full description

Bibliographic Details
Main Author:	Honorato, Aldrina Laura da Silva Costa
Other Authors:	Suen, Vivian Marques Miguel
Format:	Others
Language:	pt
Published:	Biblioteca Digitais de Teses e Dissertações da USP 2018
Subjects:	Cardiovascular Diseases Doenças Cardiovasculares Familial Hypercholesterolemia Hipercolesterolemia Familiar lipoproteína de baixa densidade low density lipoprotein, proprotein convertase subtilisin/kexin type 9 (PCSK9) proprotein convertase subtilisina kexin tipo 9 (PCSK9).
Online Access:	http://www.teses.usp.br/teses/disponiveis/17/17138/tde-07122018-091850/

Similar Items

Investigação de mutações no gene PCSK9 em famílias com diagnóstico clínico de Hipercolesterolemia Familiar
by: Aldrina Laura da Silva Costa Honorato
Published: (2018)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
by: Kosmas CE, et al.
Published: (2020-10-01)

PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
by: Yue-Wei Qian, et al.
Published: (2007-07-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
by: Gan S, et al.
Published: (2017-04-01)

Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
by: Yuki Awanami, et al.
Published: (2017-07-01)

Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data
by: Julita Anna Krahel, et al.
Published: (2020-03-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
by: Christian Abendstein Kjellmo, et al.
Published: (2018-05-01)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
by: Arman Moradi, et al.
Published: (2021-02-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Koroner Kalp Hastalarında PCSK9 E670G ve N425S Gen Varyasyonlarının Etkisinin Türk Toplumunda Değerlendirilmesi
by: Hülya Yılmaz Aydoğan, et al.
Published: (2018-04-01)

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
by: Hua Sun, et al.
Published: (2018-02-01)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01)

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
by: Florent Lalanne, et al.
Published: (2005-06-01)

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
by: Ga Eun Lee, et al.
Published: (2021-01-01)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
by: Maria Pia Adorni, et al.
Published: (2019-05-01)

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
by: Jonathan Grimm, et al.
Published: (2021-04-01)

Sex-Specific Association of Endogenous PCSK9 With Memory Function in Elderly Subjects at High Cardiovascular Risk
by: Paola G. Simeone, et al.
Published: (2021-03-01)

Computational Study of PCSK9-EGFA Complex with Effective Polarizable Bond Force Field
by: Jian Chen, et al.
Published: (2018-01-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016-07-01)

Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms
by: Johan Frostegård, et al.
Published: (2021-01-01)

Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance
by: Jean-Philippe Drouin-Chartier, et al.
Published: (2018-08-01)

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
by: Chengfeng Qiu, et al.
Published: (2017-06-01)

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
by: Greg Welder, et al.
Published: (2010-09-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

PCSK9: a convertase that coordinates LDL catabolism
by: Jay D. Horton, et al.
Published: (2009-01-01)

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
by: Matthew T. Mefford, et al.
Published: (2019-11-01)

Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis
by: Yimo Zhou, et al.
Published: (2021-03-01)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
by: Coen van Solingen, et al.
Published: (2021-07-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
by: Junlan Chuan, et al.
Published: (2019-04-01)